Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORE1: Reduced Dose Efavirenz in HIV
NCT01011413Phase 3Completed
- Sponsor
- The Kirby Institute
- Start
- Aug 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Kirby Institute. Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <200 Copies/mL at 48 weeks. Started Aug 2011; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01011413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011413.